Publications by authors named "L Meziani"
Article Synopsis
- The study investigates how different doses of radiotherapy (RT) affect the tumor immune environment and explores a strategy that combines low dose RT (LDRT) with high dose RT (HDRT) to enhance anti-tumor responses.
- Researchers conducted experiments on colorectal and breast cancer models in mice, finding that a technique called partial irradiation (PI) improved tumor control when paired with an immune treatment (anti-PD1).
- Results showed that PI reshaped immune cells in the tumor, increasing their ability to fight cancer, while also suggesting that adding a certain drug (CXCR2 antagonist) alongside RT and immunotherapy can enhance tumor control and survival rates.
Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing locally advanced human papillomavirus-positive head/neck carcinoma. The typically young patients may suffer serious and long-time side effects caused by the treatment, such as dysphagia, and hearing loss. Thus, ensuring a satisfactory post-treatment quality of life is paramount.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the combination of atezolizumab (a PD-L1 inhibitor) and stereotactic body radiation therapy (SBRT) in patients with advanced colorectal cancer (CRC) as part of the SABR-PDL1 trial.
- A group of 60 pretreated patients from five centers participated, receiving atezolizumab and follow-up SBRT, with a focus on measuring progression-free survival (PFS) and collecting immune profiling data.
- Results showed a median overall survival of 8.4 months and a PFS of 1.4 months, with the treatment being relatively well-tolerated; some patients exhibited significant responses, including stable disease and a few partial or
Purpose: The capability of ultrahigh dose rate FLASH radiation therapy to generate the FLASH effect has opened the possibility to enhance the therapeutic index of radiation therapy. The contribution of the immune response has frequently been hypothesized to account for a certain fraction of the antitumor efficacy and tumor kill of FLASH but has yet to be rigorously evaluated.
Methods And Materials: To investigate the immune response as a potentially important mechanism of the antitumor effect of FLASH, various murine tumor models were grafted either subcutaneously or orthotopically into immunocompetent mice or in moderately and severely immunocompromised mice.
Background: KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors have recently reached clinical development. Among them, MRTX849 (Mirati Therapeutics) showed encouraging clinical outcomes for the treatment of selected patients with KRAS mutated NSCLC and colorectal cancers.
View Article and Find Full Text PDF